Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.

Dold C. et al, (2023), Science translational medicine, 15

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.

Jenkin D. et al, (2023), Lancet Infect Dis

Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria

Li K. et al, (2023), Biophysical journal, 122, 144a - 145a

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209

A tool for evaluating heterogeneity in avidity of polyclonal antibodies.

Li K. et al, (2023), Front Immunol, 14

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso

Morter R. et al, (2022), Frontiers in Immunology, 13

Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank

Mentzer AJ. et al, (2022), Nature Communications, 13

Immunopeptidomic Analysis of BoLA-I and BoLA-DR Presented Peptides from Theileria parva Infected Cells.

Connelley T. et al, (2022), Vaccines, 10

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 104298 - 104298

Genome-wide association study of leprosy in Malawi and Mali.

Gilchrist JJ. et al, (2022), PLoS pathogens, 18

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.

Datoo MS. et al, (2022), Lancet Infect Dis

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Padron-Regalado E. et al, (2022), Scientific reports, 12

BIRC6 modifies risk of invasive bacterial infection in Kenyan children.

Gilchrist JJ. et al, (2022), eLife, 11

Production of a high purity, C-tagged Hepatitis B surface Antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.

Mukhopadhyay E. et al, (2022), Biotechnology and bioengineering

Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers.

Liu Y-C. et al, (2022), Science (New York, N.Y.), 377, 72 - 79

A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.

Bastard P. et al, (2022), The Journal of experimental medicine, 219

A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.

Bliss CM. et al, (2022), Molecular therapy : the journal of the American Society of Gene Therapy, 30, 2024 - 2047

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Viral Vectors Expressing Group B Meningococcal Outer Membrane Proteins Induce Strong Antibody Responses but Fail to Induce Functional Bactericidal Activity in Mice.

Marsay L. et al, (2022), The Journal of infection

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination

Sharpe HR. et al, (2022), JCI Insight

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?